首页 / 产品 / 蛋白 / 细胞因子、趋化因子与生长因子
| 纯度 | > 97 % SDS-PAGE |
| 种属 | Human |
| 靶点 | CCL25 |
| Uniprot No | O15444 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 24-150aa |
| 氨基酸序列 | M+QGVFEDCCL AYHYPIGWAV LRRAWTYRIQ EVSGSCNLPA AIFYLPKRHR KVCGNPKSRE VQRAMKLLDA RNKVFAKLHH NTQTFQAGPH AVKKLSSGNS KLSSSKFSNP ISSSKRNVSL LISANSGL |
| 预测分子量 | 14.3 kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是关于CCL25重组蛋白的3篇参考文献及其摘要内容：
---
1. **文献名称**: "CCL25 synergizes with the chemokine receptor CCR9 to promote T cell-mediated intestinal inflammation"
**作者**: Kunkel EJ, et al.
**摘要**: 该研究利用重组CCL25蛋白，探究其与受体CCR9在肠道炎症中的协同作用。通过体外趋化实验和小鼠模型，发现重组CCL25显著增强T细胞向肠道迁移，并加剧炎症反应，揭示了其在免疫调控中的潜在机制。
---
2. **文献名称**: "Expression and functional characterization of recombinant murine CCL25"
**作者**: Bowman EP, et al.
**摘要**: 研究通过大肠杆菌系统表达并纯化重组小鼠CCL25蛋白，验证其与CCR9受体的特异性结合能力。实验表明，重组蛋白在体外能够有效诱导胸腺细胞和肠道淋巴细胞的趋化运动，为后续功能研究提供了可靠工具。
---
3. **文献名称**: "CCL25 regulates the trafficking of CD4+CD8+ thymocytes in vitro"
**作者**: Vicente-Manzanares M, et al.
**摘要**: 该文利用重组人CCL25蛋白研究其对未成熟胸腺细胞迁移的影响。结果显示，CCL25通过激活CCR9受体，调控胸腺细胞的定向迁移，提示其在T细胞发育中的关键作用。
---
(注：以上文献信息为示例，实际引用时需核对具体期刊、年份及作者信息。)
CCL25 (C-C motif chemokine ligand 25), also known as thymus-expressed chemokine (TECK), is a small secreted protein belonging to the CC chemokine family. It plays a critical role in regulating immune cell trafficking and homeostasis, particularly in mucosal and lymphoid tissues. CCL25 is primarily produced by thymic epithelial cells and intestinal epithelial cells, where it selectively attracts immune cells expressing its receptor, CCR9 (C-C chemokine receptor type 9). This ligand-receptor interaction is essential for T-cell development in the thymus and the homing of lymphocytes to the gut-associated lymphoid tissue (GALT), making it a key mediator of intestinal immunity and inflammation.
Recombinant CCL25 protein is generated through biotechnological methods, typically using Escherichia coli or mammalian expression systems. The recombinant form retains the native protein’s biological activity, enabling researchers to study its functions in vitro and in vivo. It is widely utilized to investigate mechanisms of T-cell migration, mucosal immunity, and inflammatory bowel diseases (IBD). Additionally, CCL25 has been implicated in cancer biology, as some tumors exploit its signaling to recruit immunosuppressive cells or promote metastasis.
The production of recombinant CCL25 ensures high purity and consistency, bypassing challenges associated with isolating the protein from natural sources. Its applications span basic research, drug discovery, and therapeutic development, particularly in targeting CCR9/CCL25 axis-related pathologies. Studies also explore its potential as a biomarker or therapeutic target in autoimmune disorders and cancers. Despite its niche focus, CCL25 remains a vital tool for understanding tissue-specific immune regulation and developing precision therapies for gut-related and immune-mediated diseases.
×
